hera – -Translation – Keybot Dictionary

Spacer TTN Translation Network TTN TTN Login Deutsch Français Spacer Help
Source Languages Target Languages
Keybot 9 Results  www.scf-group.com
  Company Profile ǀ Apoge...  
Show textShow cached sourceOpen source URL
In addition, Apogenix’ highly qualified scientific team has developed the proprietary HERA-ligand technology platform for the development of novel fusion proteins. These fusion proteins offer clear therapeutic advantages over other biologics such as antibodies and have the potential for broad application in oncology.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine apogenix.com as primary domain
Darüber hinaus hat das hochqualifizierte wissenschaftliche Team von Apogenix die proprietäre HERA-Liganden-Technologieplattform entwickelt, auf deren Basis neuartige Proteinwirkstoffe für den breiten Einsatz in der Onkologie entwickelt werden, die im Vergleich zu anderen Biotherapeutika, wie z.B. Antikörpern, deutliche therapeutische Vorteile aufweisen.
  Pipeline ǀ Apogenix  
Show textShow cached sourceOpen source URL
Apogenix has also developed the proprietary HERA-ligand technology platform for the construction of novel hexavalent TNFSF receptor agonists for the treatment of cancer. Preclinical experiments have shown that these agonists effectively stimulate the immune system and display potent anti-tumor efficacy in different model systems, thus making them promising candidates for the treatment of solid tumors.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine apogenix.com as primary domain
Apogenix hat überdies die proprietäre HERA-Liganden-Technologieplattform zur Konstruktion von neuartigen hexavalenten TNFSF-Rezeptor-Agonisten für den breiten Einsatz in der Onkologie entwickelt. In präklinischen Experimenten konnte gezeigt werden, dass diese Agonisten das Immunsystem effektiv stimulieren und somit vielversprechende Kandidaten zur Behandlung von soliden Tumoren darstellen.
  Press Releases ǀ Apogenix  
Show textShow cached sourceOpen source URL
Apogenix Presents Data on Novel Hexavalent TNF Receptor Agonists (HERA-Ligands) at the Upcoming Annual Meeting of the American Association for Cancer Research (AACR)
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine apogenix.com as primary domain
Apogenix präsentiert erstmals Daten zu neuartigen hexavalenten TNF-Rezeptor-Agonisten (HERA-Liganden) auf der bevorstehenden Jahrestagung der American Association for Cancer Research (AACR)
  Pipeline ǀ Apogenix  
Show textShow cached sourceOpen source URL
HERA-Ligand Technology
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine apogenix.com as primary domain
HERA-Liganden-Technologie